Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia

Yixin Zou¹,²,³, Wei Xu¹,²,³ and Jianyong Li¹,²,³*

Abstract

Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years. New drugs such as ibrutinib, idelalisib, and venetoclax have achieved great success in treating relapsed and refractory (R/R) CLL. In addition, with the development of immunotherapy, chimeric antigen receptor-engineered T cells (CAR-T) therapy, a novel adoptive immune treatment, has also become more and more important in treating R/R CLL. It combines the advantages of T cells and B cells via ex vivo gene transfer technology and is able to bind targets recognized by specific antibodies without antigen presentation, thus breaking the restriction of major histocompatibility complex. So far, there have been lots of studies exploring the application of CAR-T therapy in CLL. In this review, we describe the structure of chimeric antigen receptor, the preclinical, and clinical results of CAR-T therapy against CLL, along with its adverse events and advances in efficacy.

Keywords: Chimeric antigen receptor, Chronic lymphocytic leukemia, Immunotherapy, T cell, Toxicity

Background

Chronic lymphocytic leukemia (CLL) is a common type of B cell chronic lymphoproliferative disorder with varied treatment options as a result of its heterogeneity. It mainly affects the elderly, and the 5-year survival rate for CLL patients is 79.2% [1–3]. To date, it is still an incurable disease and a lot of patients, especially those with tumor protein 53 (TP53) disruption, will relapse rapidly after first-line immunochemotherapy-based treatment. Therefore, new weapons are needed. New drugs such as ibrutinib and venetoclax have achieved great success even in relapsed and refractory (R/R) CLL. Besides, the great potential of immunotherapy in CLL also has already aroused worldwide interest.

Chimeric antigen receptor-engineered T cells (CAR-T) therapy, a novel adoptive immune treatment initially invented in 1989, is now attracting more and more attention because of its promising effects even for highly refractory hematological malignancies. Through gene transfer technology, T cells can express chimeric antigen receptor (CAR) targeting specific antigens. The advantage of CAR-T cells over conventional autologous T cells is that by equipping T cells with CAR, it can identify antigens via major histocompatibility complex independent recognition. Preclinical and clinical results show that CAR-T therapy is a feasible way to treat R/R CLL. By summarizing the recent advances, we hope to introduce in detail the application of CAR-T therapy in CLL and provide a new perspective for R/R CLL treatment.

Structure of chimeric antigen receptor

CAR comprises four important elements, including an extracellular targeting domain, a hinge or spacer, a transmembrane domain and an intracellular signaling domain [4, 5]. Extracellular targeting domains are usually single chain variable fragments (scFv) consisting of heavy chain variable regions and light chain variable regions of immunoglobulin (Ig) [6]. A spacer/hinge, which often derives from human IgG1, IgG4, and CD8, is designed to connect scFv with transmembrane domain [7–9]. The length of this structure alters CAR activation and scFv flexibility by determining the distance between scFv and tumor antigen. A transmembrane motif takes auxiliary responsibility to assist scFv and intracellular signaling domain, and CD3ζ/CBD28 are common molecules in it.

* Correspondence: lijianyonglm@126.com
¹Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
²Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Intracellular signaling domain is involved in CAR-T cells activation and proliferation. It is comprised of CD3ζ or FcRIγ and co-stimulatory signaling domains such as CD28 or CD137 \cite{10, 11}. Up to now, there are at least four generations of CAR-T cells, and the second generation is most commonly used. First generation has a single signaling molecule, and CD3ζ is most commonly used. Second generation can generate double signals via CD3ζ and a co-stimulatory domain \cite{12, 13}, and third generation has two co-stimulatory molecules. Fourth generation consists of multiple types, including TRUCK T cells \cite{14} and CAR-T with suicide genes \cite{15, 16}. Currently, most scFvs are murine-derived which may lead to clearance of CAR-T cells due to immunogenicity so that weakening the efficacy of the treatment. To solve this problem, CAR-T with human-derived scFv is developed and is superior to that with murine-derived scFv \cite{17}. In addition, a new idea “universal CAR-T cells,” which are derived from healthy donors, could overcome the problems of dysfunction of T cells in patients and make “off-the-shelf” come true by editing genes of T cell receptor and human leukocyte antigen \cite{18, 19}. CAR-T cells can be directed against tumor with certain antigen. However, under most circumstances, normal cells and tumor cells share some important antigens. In consideration of safety, researchers add programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-based inhibitory chimeric antigen receptors (iCAR) that can bind ligands on common cells to CAR-T cells. On this occasion, if these CAR-T cells come across normal cells, they will fail to activate \cite{20}. By contrast, some investigators construct new CAR-T cells carrying chimeric co-stimulatory receptors (CCR) recognizing antigens existed in cancer cells so that they can only be activated when binding to two antigens expressed on tumor cells at the same time \cite{21, 22}. Target antigen loss is a common reason for the failure of CAR-T therapy, but losing two antigen at the same time is rare. As a result, CD19-CD20 bispesific CAR-T cells are designed and showed their efficacy in killing CD19-negative CLL cells \cite{23}. In addition, switchable dual-receptor CAR-engineered T cells were designed in order to make CAR-T cells controllable in the aspect of activation and toxicity \cite{24}.

**The application of CAR-T therapy in CLL: preclinical and clinical data**

Choosing a satisfying target is a key step for CAR-T therapy. Chimeric antigen receptor can bind to a wide range of antigens that exist on the surface of cells, such as proteins, carbohydrate, ganglioside, proteoglycan, and heavily glycosylated protein \cite{25–27}. Scientists hope to find a specific antigen only expressed on tumor cells, but this type of antigen has been difficult to come across. Other principles of a good target are that antigens are highly expressed on tumor cells and are the key elements to their function, while on normal cells their expression is weak or negative \cite{28}. In 2009, Kochenderfer and his colleagues \cite{29} had validated that CAR-T cells can specifically kill primary CLL cells. To date, a lot of potential antigens, such as CD19 and CD23, have been studied in preclinical and clinical research studies of CLL. Clinical trials of CAR-T therapy for patients with CLL are shown in Table 1.

**CD19**

CD19, a B cell surface protein, is expressed on almost all malignant B cells, normal B cells at different stages, and follicular dendritic cells, but hardly on other cells \cite{30, 31}. Moreover, it is vital for B cell activation. The first clinical trial for CLL was launched in 2011, evaluating the efficacy of autologous anti-CD19 CAR-T cells (CD28 as the co-stimulatory molecule) in eight R/R patients. The first four patients did not receive cyclophosphamide while the next four patients did. Patients with and without cyclophosphamide preconditioning were infused with $(1.2–3.0) \times 10^7$ CAR-T cells/kg and $(0.4–1.0) \times 10^7$ CAR-T cells/kg, respectively. Eventually, patients without cyclophosphamide-conditioning had no response to CAR-T therapy and died from disease progression, while for the four patients treated with cyclophosphamide, three exhibited stable disease (SD), and one remained progressive (PD) \cite{32}. The toxicities mainly included grades 1–2 fever, rigors, chills, and grade 3 febrile neutropenia. One patient taking $3.2 \times 10^7$ CAR-T cells without cyclophosphamide suffered from grade 5 hypotension and renal failure. In other two studies, totally eight R/R CLL patients got cyclophosphamide and fludarabine followed by $(0.1–2.8) \times 10^7$ CAR-T cells/kg. Eventually, four patients achieved complete remission (CR), three partial remission (PR), and one SD \cite{33, 34}. Grades 3 and 4 adverse events usually occurred in 8 days after CAR-T cells infusion, including hypotension, fever, acute renal failure, hypoxemia, hyperbilirubinemia, capillary leak syndrome, obtundation, liver enzymes/creatinine/electrolyte abnormalities, upper extremity thrombosis, and urinary tract infection. Besides, because of the elimination of normal B cells, some patients developed hypogammaglobulinemia. These results showed that CAR-T therapy did have the potential to control the disease resistant to chemotherapy. Compared with patients without previous lymphodepleting therapies, wonderful capacity of proliferation and persistence of CAR-T cells were seen in preconditioning patients because preconditioning might enhance the proliferation and persistence of CAR-T cells by reducing tumor burden, releasing tumor antigens, inducing inflammation, and eliminating immunosuppressive cells such as regulatory T cell and myeloid-derived suppressor cells.
### Table 1: Open clinical trials of CAR-T-cell therapy for patients with CLL

| ClinicalTrials ID | Trial title/description                                                                                     | Target       |
|-------------------|-----------------------------------------------------------------------------------------------------------|--------------|
| NCT02640209       | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CAR-T) Combining With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) | CD19         |
| NCT02644655       | Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia | CD19         |
| NCT02456350       | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies     | CD19         |
| NCT03076437       | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies     | CD19         |
| NCT01865617       | Laboratory T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | CD19         |
| NCT02933775       | CD19-directed Autologous Cells (CAR-CD19 T Cells)                                                        | CD19         |
| NCT02672501       | A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia | CD19         |
| NCT01853631       | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | CD19         |
| NCT03110640       | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma    | CD19         |
| NCT01747486       | CD19 Redirected Autologous T Cells                                                                       | CD19         |
| NCT03085173       | A Trial of “Armed” CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies    | CD19         |
| NCT02685670       | Competitive Transfer of #CD19-TCRz-CD28 and #CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma     | CD19         |
| NCT02782351       | Humanized CAR-T Therapy for Treatment of B Cell Malignancy                                               | CD19         |
| NCT00881920       | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHANKALL     | Kappa        |
| NCT02050347       | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-All HSTC(CARPASCIO)              | CD19         |
| NCT02963038       | CAR T Cells for Refractory B Cell Malignancy                                                             | CD19         |
| NCT03068416       | CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy                             | CD19         |
| NCT03166878       | A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma           | CD19         |
| NCT03448393       | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | CD19/CD22    |
| NCT03191773       | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies                | CD19         |
| NCT02132624       | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial         | CD19         |
| NCT03277729       | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | CD20         |
| NCT02851589       | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | CD19         |
| NCT02819583       | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma                    | CD19         |
| NCT03302403       | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | CD19         |
| NCT02706392       | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies                  | ROR1         |
| NCT01626495       | Phase I/IA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma | CD19         |
| NCT01475058       | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant                                      | CD19         |
| NCT03331198       | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004) | CD19         |
patients, were infused with (0.14–TP53 total of 14 CLL cases, including 6 CAR-T cells transfected with lentivirus [10, 40, 41]. A

cles assessing the values of anti-CD19-CD137-CD3ζ in Table 2. So far, there have been three published arti-

signaling domain based on published data was presented coupled with CD28 could kill tumor cells effectively in

CAR-T cells. Previous reports demonstrated that CAR-T to cyclophosphamide alone.

and cyclophosphamide for preconditioning was superior

(87.5% vs 25.0%), which illustrated that using fludarabine

because of murine single chain variable fragment. There-

fore, preconditioning was needed to suppress autoimmune

in CLL patients, which may restrict the cap-

exhausted in CLL patients, which may restrict the cap-

ity in order to slow down the clearance of CAR-T cells

Furthermore, these studies revealed that, in spite of receiving lower number of CAR-T cells, patients who got
cyclophosphamide and fludarabine had higher overall re-
sponse rate than those with cyclophosphamide only

(87.5% vs 25.0%), which illustrated that using fludarabine

cyclophosphamide for preconditioning was superior to cyclophosphamide alone.

CD137, also known as 4-1BB, affects the persistence of

CAR-T cells. Previous reports demonstrated that CAR-T coupled with CD28 could kill tumor cells effectively in

the first 7 days, and CAR-T equipped with CD137 persisted longer [38, 39]. A comparison of CAR-T cells’
signaling domain based on published data was presented in Table 2. So far, there have been three published arti-
cles assessing the values of anti-CD19-CD137-CD3ζ CAR-T cells transfected with lentivirus [10, 40, 41]. A

total of 14 CLL cases, including 6 TP53 deficient patients, were infused with (0.14–11) × 10^9 CAR-T cells

after chemotherapy conditioning (six with bendamustine, three with fludarabine/cyclophosphamide, and five

with pentostatin/cyclophosphamide). Eventually, four patients achieved CR and four PR. Totally nine patients

suffered from grades 1–4 cytokine release syndrome (CRS), and the median occurrence day was 7. Toci-
lizumab or glucocorticoid was used in five patients, and four patients were admitted into the intensive care unit
(ICU) because of hypotension and hypoxemia. In

addition, neurotoxicity was seen in five patients, and almost all patients whose CAR-T treatment was effective

had B cell aplasia and hypogammaglobulinemia. CAR copies could be detected after 1 year in patients with CR.

Therefore, CAR-T cells coupled with CD137 transfected with lentivirus also showed beneficial and persistent

effects on R/R CLL, similar to those with CD28.

The function of T cells is usually impaired, even

exhausted in CLL patients, which may restrict the cap-

acity of CAR-T cells. Accordingly, relevant studies using

allogeneic retrovirally transduced anti-CD19-CD28ζ

CAR-T cells were carried out in the past 5 years in order to

explore whether using donor-derived T cells was a

good approach to overcome this limitation. A total of

nine R/R CLL subjects who relapsed after allogeneic

hematopoietic stem-cell transplantation took part in

clinical trials, and none of them received chemotherapy

conditioning before infusing (1.5–12) × 10^7/m2 or (0.4–3.1) × 10^6/kg CAR-T cells. Consequently, one patient

exhibited CR, two PR, two SD, and four PD. No graft-versus-host disease occurred after infusion, and

common side effects were fever and hypotension. Tumor

lysis syndrome was seen in one patient [42–44]. Lack of

previous chemotherapy conditioning and low dosage of

CAR-T cells may account for the relatively low response rate. However, donor-derived CAR-T therapy is still a

promising approach for treating R/R CLL because of the

excellent state of donor T cells and graft versus leukemia

effects, and someday “off-the-shelf” may be possible [45].

In the era of novel drugs, ibrutinib, a Bruton’s tyrosine

kinase (BTK) inhibitor, is the first choice for first-line

and R/R therapy for CLL with 17p deletion or TP53 muta-

tion [46]. It remains unclear how to treat CLL patients

after failure of ibrutinib. Turtle et al. [11] evaluated the

feasibility of using CAR-T therapy for CLL patients who

were refractory to ibrutinib. It was a dose escalation trial, and a total of 24 patients, most of whom had a complex

karyotype or 17p deletion, received lymphodepleting conditioning followed by infusion of 2 × 10^6, 2 × 10^7, or

2 × 10^5 CAR-T cells/kg. The overall response rate was

71% at 4 weeks. The percentage of patients who were

absent of marrow disease detected by flow cytometry

and absent of marrow malignant immunoglobulin heavy

chain (IGH) clone detected by deep IGH sequencing was

88% and 58%, respectively. However, the incidence of

CRS and neurotoxicity was 83% and 33%, respectively,

which was higher than that in previous reports. The

number of grades 1–2 CRS, grade 4 CRS, and grade 5

CRS were 18, 1, and 1, respectively. The number of

grades 1–2, grade 3, and grade 5 neurotoxicity were 2, 5,

and 1, respectively. Neurotoxicity was reversible, and it

was always associated with CRS. In total, six patients

needed tocilizumab or glucocorticoid for CRS, and two

patients needed ICU treatment for neurotoxicity. Positron emission tomography-computed tomography

(PET-CT) was useful for lymph node response evaluation in CAR-T therapy. Some CLL patients classified as


| ClinicalTrials ID | Trial title/description | Target |
|-------------------|-------------------------|--------|
| NCT01593696      | Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | CD19 |
| NCT03436771      | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | CD19 |
| NCT01864889      | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 | CD19 |
| NCT03050190      | A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies | CD19 |
PR by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) were restaged as CR after PET-CT scan due to no lesions with fluorodeoxyglucose uptake. Despite low infusion dose, the overall response rate acquired in ibrutinib-resistant patients were satisfactory comparing with results reported by Brentjens et al. [32] in 2011. In Brentjens et al. study, all patients had bulky lymphadenopathy, and did not receive preconditioning or only got cyclophosphamide. The mean CD4/CD8 ratio in cellular products was 10.5, which was much higher than 1, the ideal ratio for CAR-T therapy [47]. The persistence time and the ability of cytokine release of CAR-T cells were inferior to those in Turtle’s research, which might be due to the relatively low level of manufacturing technique of CAR-T cells in 2011. Besides, ibrutinib could improve T cell function in CLL patients, and eventually, enhance the efficacy of CAR-T therapy. In summary, CAR-T therapy is a good choice for patients after failure of ibrutinib. It is worth mentioning that control of adverse events and application of PET-CT are vital in this process.

Additionally, combining ibrutinib with anti-CD19 CAR-T was a promising idea to treat heavily pretreated CLL individuals or untreated CLL patients with TP53 disruption. A total of 10 CLL patients were enrolled in a pilot trial and none of them achieved CR when treated with ibrutinib. They were lymphodepleted before CAR-T infusion and continued to take ibrutinib. At 3 months, 89% of evaluable patients achieved a minimal residual disease (MRD)-negative marrow CR. CRS was seen in nine patients, but tocilizumab was not required. Compared with single ibrutinib or CAR-T, combination therapy had a better outcome and controllable toxicity, and therefore, ibrutinib and CAR-T had a synergistic effect to treat high-risk CLL patients, especially those with TP53 disruption [48].

Using CAR-T cells as a consolidative therapy was a novel concept presented by Geyer and his colleagues [49]. Totally eight patients who had residual CLL cells after pentostatin, cyclophosphamide, and rituximab treatment were enrolled in this clinical trial. All patients had poor prognostic factors such as unmutated immunoglobulin heavy chain variable region gene. Patients received low-dose chemotherapy with 600 mg/m² cyclophosphamide, followed by infusion of $3 \times 10^6$, $1 \times 10^7$, or $3 \times 10^7$ anti-CD19-CD28-CD3ζ CAR T cells/kg.

### Table 2

| Signal | Target | Study | Number | Preconditioning | Source | Cell dose | ORR and CRR |
|---|---|---|---|---|---|---|---|
| CD28 | CD19 | 2011.Brentjens | 8 | None (3) | Autologous | Without preconditioning: 1.2–3.0 $\times 10^7$/kg | ORR 1/7 (14.3%) CRR 0/7 (0%) |
| | | | | | | With preconditioning: 0.4–1.0 $\times 10^7$/kg | |
| | | 2012.Kochenderfer | 4 | Fludarabine + cyclophosphamide (4) | Autologous | 0.3–2.8 $\times 10^7$/kg | ORR 3/4 (75.0%) CRR 1/4 (25.0%) |
| | | | | | | 1–4 $\times 10^6$/kg | ORR 4/4 (100%) CRR 3/4 (75.0%) |
| | | 2013.Cruz | 4 | None | Allogeneic | 1.5–12 $\times 10^7$/m² | ORR 1/4 (25.0%) CRR 0/4 (0%) |
| | | | | | | 0.4–3.1 $\times 10^6$/kg | ORR 2/5 (40.0%) CRR 1/5 (20.0%) |
| | | 2015.Kochenderfer | 4 | Fludarabine + cyclophosphamide (4) | Autologous | 3 $\times 10^6$/kg, 1 $\times 10^7$/kg, 3 $\times 10^7$/kg | ORR 2/8 (25.0%) CRR 2/8 (25.0%) |
| | | | | | | 0.4–3.1 $\times 10^6$/kg | ORR 0/2 (0%) CRR 0/2 (0%) |
| | | 2016.Kremer | 8 | Cyclophosphamide (8) | Autologous | 9.1 $\times 10^6$/m², 1.6 $\times 10^6$/m² | ORR 2/8 (25.0%) CRR 2/8 (25.0%) |
| | | | | | | 600 mg/m² | ORR 8/14 (57.1%) CRR 4/14 (28.6%) |
| | | 2011.Kalos | 14 | Bendamustine (6) | Autologous | 0.14–11 $\times 10^8$ | ORR 16/23 (69.6%) CRR 4/23 (17.4%) |
| | | 2011.Porter | Fludarabine/cyclophosphamide (3) | Autologous | 2 $\times 10^7$/kg, 2 $\times 10^6$/kg | ORR 0/2 (0%) CRR 0/2 (0%) |
| | | 2015.Porter | Pentostatin/cyclophosphamide (5) | Autologous | 2 $\times 10^7$/kg, 2 $\times 10^6$/kg | ORR 0/1 (0%) CRR 0/1 (0%) |
| | | 2017.Turtle | Fludarabine + cyclophosphamide (21) | Autologous | 2 $\times 10^7$/kg, 2 $\times 10^6$/kg | ORR 16/23 (69.6%) CRR 4/23 (17.4%) |
| | | | | | | 3 $\times 10^6$/kg | One died before evaluation |

**Abbreviations:** ORR overall response rate, CRR complete remission rate
Eventually, two patients achieved CR, and no severe CRS and neurotoxicity were seen after CAR-T cells infusion. Persistence time of CAR-T cells was relatively short in these CLL patients, with the longest time was 48 days after infusion.

CD23
CD23 (FcεRII), a low-affinity IgE receptor, is involved in IgE synthesis. The typical phenotype of CLL cells is CD5+CD23+, which makes CD23 a potential target for CLL therapy. The feasibility and safety of anti-CD23 CAR-T cells were tested in a recent study [50]. Notably, the results showed that in vitro, CAR-T cells could effectively lyse either CLL-like MEC-1 cells or primary CLL cells and release cytokines such as interferon-γ (IFN-γ) without serious toxicity for normal B cells. Additionally, anti-CD23 CAR-T cells can slow the proliferation of tumor cells in a CLL xenograft mouse model. Therefore, preclinical results showed that anti-CD23 CAR-T cells could eliminate CLL cells effectively in vitro and in vivo. Similar to the sequential infusion of anti-CD19 and anti-CD22 CAR-T cells in treating R/R acute lymphocytic leukemia (ALL) as well as B cell lymphoma, and combined infusion of CD19 and B cell mature antigen (BCMA)-specific CAR-T cells for R/R multiple myeloma, combining anti-CD19 with anti-CD23 CAR-T cells to treat R/R CLL might be a promising strategy as well.

ROR1
Tyrosine kinase-like orphan receptor 1 (ROR1), also known as neurotrophic tyrosine kinase, receptor-related 1, is a member of the receptor tyrosine kinase-like orphan receptor family. ROR1 is highly expressed on CLL cells, but not on normal B cells, which makes ROR1 an ideal tumor-specific antigen for antitumor immunotherapy [51]. Preclinical data demonstrated that CAR-T cells can accurately recognize autologous ROR1-expressing tumor cells or cell lines and could serve as a powerful weapon to eliminate chemotherapy resistant CLL cells. However, it should be noted that on-target/off-tumor toxicity must be taken into consideration when using anti-ROR1 CAR-T because of its expression on other normal tissues, such as parathyroid, pancreatic islet cells, and gastrointestinal tract [52–55].

κ light chain
CLL cells are originated from monoclonal B lymphocytes and restrictively express κ or λ light chain. Unlike CD19, CAR-T cells targeting κ or λ chain can only kill a fraction of normal B cells, which may alleviate the adverse effect of B cell aplasia. A phase I dose escalation clinical trial, in which two κ+ R/R CLL patients were involved, was designed to evaluate the role of anti-κ CAR-T cells in hematologic malignancies. Neither of them received lymphodepleting conditionings. One patient exhibited no response after infusion with 9.1 × 10⁷/m² CAR-T cells once, and the other, who was infused with 1.6 × 10⁸/m² CAR-T cells twice, eventually showed stable disease lasting 6 weeks. No serious adverse events were seen in these two patients. Low infusion dosage, low expression of κ on the surface of CLL cells, and no lymphodepleting conditionings may explain these unsatisfactory results and the feasibility of anti-κ CAR-T cells in CLL needs further validation [56].

CD20
CD20 is a mature B cell antigen limitedly existing on the surface of CLL cells. Nowadays, many novel immuno-therapy drugs targeting CD20, such as rituximab, ofatumumab, and GA101, can exert their function to kill CLL cells by antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity. However, CLL cells may be gradually refractory to these drugs after a few days of therapy by downregulating the expression of CD20. A recent study showed that CLL cells, which were resistant to CD20 monoclonal antibodies, could be lysed by anti-CD20 CAR-T cells. Further study demonstrated that the threshold density of CD20 was nearly 200 molecules per cell for CAR-T lysis activity and several thousand for CAR-T cytokine release [57]. Therefore, if we can choose a target whose density on CLL cells is between the threshold of lysis activity and cytokine release, the incidence of CRS may greatly decrease.

FcμR
Immunoglobulin M Fc receptor (FcμR), also known as the Fas apoptotic inhibitory molecule-3 or TOSO, is selectively expressed on CLL cells and limitedly expressed by normal B cells. Faitschuk et al. [58] confirmed that anti-FcμR CAR-T cells, derived from CLL patients with different disease status, could effectively kill CLL cells in vitro and in vivo by releasing a variety of factors, but not kill normal cells, thus avoiding off-target effect to a certain degree. Preclinical data reveals that FcμR is superior to previous target antigens such as CD19 and CD23 and has the potential to have a place in CLL immunotherapy.

CD16 V158
All of the CAR-T cells mentioned previously directly kill tumor cells. It is known to all that natural killer cells, which have a CD16 V158 variant, can exert ADCC by binding to the Fc fragment of immunoglobulin. Based on it, Kudo et al. [59] designed a kind of CAR-T cells containing CD16 V158 scFv so that they could eliminate CLL cells effectively by the regulation of rituximab at a
small count. Besides, rituximab combined with anti-CD16 V158 CAR-T cells showed a better capacity to kill CLL cells than rituximab only. In all, anti-CD16 V158 CAR-T cells can enhance the efficacy of rituximab and have the potential to be a universal approach in the future.

**Adverse events**

CRS, B cell aplasia, neurotoxicity, and infection are common adverse events of CAR-T cell therapy in CLL [60–62]. When encountering target cells, CAR-T cells are activated in a short time and release many kinds of cytokines such as interleukin (IL)-6, IL-10, tumor necrosis factor (TNF)-α, and IFN-γ at high-levels. In addition, macrophages, monocytes, natural killer cells, and dendritic cells can also be involved in the inflammatory response by producing inflammatory factors under the stimulation of CAR-T cells, target cells, and inflammatory mediators [63]. Recent studies showed that monocytes/macrophages were the major sources of IL-1 and IL-6 during CRS [64, 65]. The severity of CRS is positively associated with high bone marrow tumor burden, thrombocytopenia before preconditioning, number of CAR-T cells, and so on [61]. The incidence of CRS is relatively high in CLL (CRS occurs in nearly 83% CLL patients), especially for patients who used ibrutinib previously, which may be due to the recovery of T cell exhaustion [11]. CRS can affect multiple organ systems, and clinical symptoms of CRS in CLL are various, ranging from fever and hypoxia to renal failure and even death [34]. IL-6 receptor antagonist tocilizumab and corticosteroids are two desirable regimens which are often used to attenuate symptoms when necessary [66]. Tocilizumab is used with the dose of 4 to 8 mg/kg (not to exceed 800 mg) and infused over 1 h. When CRS is refractory to tocilizumab, methylprednisolone can be used with the dose of 1–2 mg/kg every 12 h. In addition, dexamethasone can be used with the dose of 10 mg every 6 h. All these drugs are used according to different clinical symptoms [67]. Because CD19 is widely expressed on B cells, anti-CD19 CAR-T cells can both eliminate CLL cells and normal B cells, causing B cell aplasia, which is characterized by the deficiency of B cells and immunoglobulin [33]. When it occurs, extra-immunoglobulin infusion is a feasible solution in order to refrain from infection [12]. In the past 5 years, neurologic toxicity, whose mechanism remains unclear, has been reported in a few CLL patients and clinicians are gradually aware of this issue. The incidences of grades 1–3 neurotoxicity and grades 4–5 neurotoxicity in CLL are 29% and 4% respectively [62]. Typically, its symptoms include delirium, aphasia, seizure, etc. Time of first fever after the CAR-T cell infusion is negatively correlated with the severity of neurotoxicity. Luckily, most neurologic toxicity is reversible and can recover spontaneously without further treatment. At present, CAR-T-cell-therapy-associated toxicity 10-point neurologic assessment score is recommended to test encephalopathy syndrome of patients. When neurologic toxicity is severe, high-dose corticosteroids are recommended to use. Additionally, anti-IL-6 therapy such as tocilizumab or siltuximab can be used if neurologic toxicity is associated with concurrent CRS [68]. Peak level of CAR-T cells in blood is positively associated with efficacy and toxicity in CLL. When the number of peak CD8+ and CD4+ CAR-T cells approximately reach to 100/μl and 30/μl, respectively, the estimated probability of marrow MRD-negative CR, grade ≥ 2 CRS and grade ≥ 3 neurotoxicity are 95%, 60% and 30%, respectively [61]. Infection is a severe toxicity after CAR-T treatment because of hypogammaglobulinemia and neutropenia, sometimes even causing death. The incidence of grade ≥ 3 infection in CLL is 21%–25% according to previous reports and is significantly lower than ALL. Bacteria are the most common causes, and viruses as well as fungi are also involved in it [60]. Top-level antibiotics, antifungal agents, and antiviral agents are indispensable when infection occurs. According to the latest data of ALL, CLL, and lymphoma, among events with specific pathogens, all bacterial infections were opportunistic infections, including coagulase-negative *Staphylococcus aureus* (4/11), *Streptococcus* (2/11), *Enterococcus faecium* (1/11), *Escherichia coli* (1/11), *Acinetobacter ursingii* (1/13), *Stenotrophomonas maltophilia* (1/11), and *Capnoctyphoga spuitigena* (1/11). *Mycoplasma hominis* was also reported in one patient. Opportunistic infections of viruses included cytomegalovirus (1/13) and Epstein-Barr virus (2/13), and fungal infections included *candida* (4/5) and *Aspergillus ustus* (1/5). Prior anti-tumor treatment regimens ≥ 4, high dose of CAR-T cells, ANC < 500 cells/μl on the day of infection and high grade of CRS/neurotoxicity were high-risk factors of infection [60].

**Advances in efficacy**

CAR-T cells can effectively eliminate CLL cells, however, not all R/R CLL patients can benefit from this treatment. Previous clinical trials revealed that the overall response rate was 53% [69], but only 26% of individuals could achieve sustained remission [70]. As a consequence, finding feasible biomarkers to predict efficacy and exploring valid strategies to improve functions of CAR-T cells are essential in order to take full advantage of this weapon.

Fraietta et al. [70] retrospectively analyzed 41 R/R CLL patients who received CAR-T cell therapy, and by comparing the different characteristics of effective group and invalid group, they found that efficacy of CAR-T cells was determined by intrinsic potency, memory-related
gene expression, subpopulation, cytokines, and so on, while it was not associated with age, previous treatment, tumor burden, or TP53 states. After infusion, the number of CAR-T cells in peripheral blood would immediately decline to a low level because of redistribution in peripheral blood, bone marrow, and other tissues, and then undergo rapid expansion. During the process of manufacture and infusion, CAR-T cells derived from CR patients showed superior capacity of expansion and persistence than nonresponding (NR) patients, which was reflected in the higher peak level and the longer half-life, but time to peak level was no different between two groups [69]. These demonstrated that high peak absolute number of CAR-T cells, favorable reactivity to target cells, and persistent existence were indispensable in guaranteeing efficacy. Transcriptomic profiles showed that CAR-T cells from CR patients were enriched in early memory-associated genes while T cells from NR patients showed upregulated expression of late memory, effector, apoptosis, or aerobic glycolysis-related genes. Regarding cell types, the frequency of CD8+ T memory stem cells (TSCM) and CD27+CD45RO−CD8+ T cells were higher in CR patients than in NR patients. The differentiation of T cells is from early memory to effector memory stage, and metabolism changes from anabolism to catabolism. The differences of transcriptomic profiles and cell types of CAR-T cells between CR and NR patients suggested that CAR-T cells from CR patients are in early stage of differentiation and have strong proliferative ability and long-term survival, while CAR-T cells from NR patients are in terminal stage and have reasonable but unsustainable effector function [71]. Additionally, infusing CD27+PD-1−CD8+ CAR-T cells is essential in order to achieve favorable efficacy because CD27+PD-1−CD8+ CAR-T cells had high expression of IL-6 receptor-β chain and when stimulated by IL-6, levels of phosphorylated signal transducer and activator of transcription 3 (STAT3) rose and CAR-T cells quickly expanded. No significant difference was seen in the subset of CD4+ T cells between CR and NR patients. Moreover, concentrations of serum IL-15 and IL-6 were higher in CR patients than in NR patients, which are useful for CAR-T cells' proliferation.

Early immune deficiency is a hallmark of CLL patients, and the prominent feature is T-cell exhaustion. Under the stimulation of a large number of malignant B cells like chronic viral infections, T cells gradually lose vigor and vitality [72]. In addition, drugs like fludarabine can also have an immunosuppressive impact on T cells, especially for CD4+ T cells. Compared with healthy persons, the expression of exhaustion markers, such as PD-1, CD160, and CD244, is upregulated on the surface of T cells from CLL patients. Besides, CD8+ T cells also show impaired function of proliferation, cytotoxicity, and cytolysis, while the ability of cytokine release is normal [73]. Moreover, CAR-T cells derived from CD4+ naïve T cells (TN) cells of CLL patients show the inferior ability of expansion and express a higher level of PD-1 than healthy individuals [72]. On this occasion, CAR-T cells derived from CLL patients are unable to expand and kill neoplasms normally. Consecutive ibrutinib treatment for more than 20 weeks can augment CAR-T cells' ability in the aspects of proliferation, persistence, and cytotoxicity in vitro and in vivo, while also promote the reconstitution of cellular immune by reducing the expression of immunosuppressive molecule PD-1 on CD8+ T cells and CD200 on B-CLL cells, increasing the IFN-γ secretion of CD8+ T cells, inhibiting IL-2 inducible T-cell kinase in CD4+ T cells, driving CD4+ T cells to develop into T helper 1-type, and increasing T cell repertoire diversity [74, 75]. Results of combining CAR-T cells with ibrutinib in CLL xenograft models were consistent with those in the clinical trials [48].

According to the different differentiation states, cell surface molecules and functions, T cells are mainly divided into four subgroups: TN, effector memory T cells (TEM), central memory T cells (TCM), and T effector cells (Teff) [71]. Previous studies demonstrated that in CLL treated with either CD4+ or CD8+ CAR-T cells, TN, TEM, and TCM were superior to TEM and Teff in anti-tumor activity, and they showed great abilities of proliferation and cytotoxicity. Unfortunately, CAR-T cellular products of CLL patients always exhibit low TN/TEff ratio and thus can only exert limited function in subsequent therapy. IL-7/IL-15 can induce CAR-T cells to differentiate into TN, TSCM, while CAR-T cells stimulated by IL-2 are susceptible to become TEM and regulatory T cells. Therefore, it is a good choice to use IL-7/IL-15 as stimulants in the process of manufacture [72]. In addition, cooperativity is seen when using TN and TCM at the same time, and a defined ratio of CD4/CD8 such as 1:1 lead to better outcomes [47, 76]. Unfortunately, the CD4/CD8 T cells ratio of heavily pretreated CLL patients is far from 1:1 and the subsets are mainly TEM and Teff. Therefore, reallocating CD4/CD8 ratio and choosing TN and TCM by sorting T cells according to different phenotype are desirable methods to enhance CAR-T efficacy in CLL.

TET2 can control the proliferation of blood cells by regulating their formation. A recent study demonstrated that in a CLL patient who received CAR-T therapy, the structure of TET2 was disrupted when CAR lentivirus inserted into it, and consequently, CAR-T cells could proliferate capriciously without the inhibition of TET2. In this condition, more than 90% of CAR-T cells in this patient's body have the same T cell receptor beta repertoire, which means they are from the same cell. What is more, CD8+ CAR-T cells with disrupted TET2 tend to differentiate into TCM, characterized as early memory,
rather than $T_{ir}$, so that they can last for a long time, and patients can maintain CR status. However, these changes may result in uncontrollable proliferation of CAR-T cells, which could generate another form of leukemia and eventually do more harm than good to CLL patients. To solve this problem, adding suicide genes or CD20 antigen into $TET2$ disrupted CAR-T cells should be taken into consideration in order to ensure the safety of patients [77].

Conclusions
In the last 2 years, enormous progress was witnessed in the aspect of CAR-T therapy for CLL. However, no comprehensive review had been reported so far. This review summarizes the development of CAR-T therapy in CLL and is intended to raise physicians’ awareness of cellular therapy. Nowadays, CAR-T therapy, a promising adoptive T cell immunotherapy, has become more and more important in the treatment of CLL. As an incurable disease, CLL will relapse after a few years. For patients with adverse prognostic features, such as $TP53$ disruption and unmutated immunoglobulin heavy chain variable region, their diseases will either relapse in a short time or can be resistant to traditional immunotherapy. Even in the era of novel drugs, drug resistance will occur in some patients. CAR-T therapy can effectively eradicate CLL cells in R/R patients, even for those resistant to ibrutinib. At present, CAR-T therapy and stem cell transplantation are recommended as ultimate weapons for R/R CLL patients [78]. In general, the overall response rate is 53% [69], but only 26% of individuals can achieve sustained remission [70]. Preconditioning is necessary before infusion of CAR-T cells, and adverse events are manageable with current infusion dose. Because of the heterogeneity of these clinical trials, no significant difference is seen between co-stimulatory molecule CD28 and CD137. In general, the ALL patients are younger than CLL patients. Besides, the microenvironment of CLL inhibits the activation and proliferation of T cells. These two reasons account for the inferior efficacy of CAR-T therapy for CLL than that for ALL [79, 80]. Certainly, many problems need to be solved in CAR-T therapy for CLL. For example, which antigen to choose, how to alleviate adverse events, and how to enhance efficacy. Furthermore, T cell senescence and CAR-T cell exhaustion receive more and more attention [81]. To some extent, these problems limit the application of CAR-T therapy in CLL. In the future, combination with new drugs such as ibrutinib, venetoclax, and idelalisib, and sequential infusion of CAR-T cells targeting multiple antigens like CD19, CD23, and FcμR may be the trend of CAR-T therapy for CLL. Furthermore, researchers should try their best to formulate suitable projects to treat CLL patients with CAR-T therapy, so that eventually, patients can benefit from this weapon.

Abbreviations
ADCC: Antibody-dependent cell-mediated cytotoxicity; ALL: Acute lymphocytic leukemia; BCMA: B cell mature antigen; BTK: Bruton's tyrosine kinase; CAR: Chimeric antigen receptor; CAR-T: Chimeric antigen receptor-engineered T cells; CCR: Chimeric co-stimulatory receptor; CLL: Chronic lymphocytic leukemia; CR: Complete remission; CRS: Cytokine release syndrome; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; FcμR: Immunoglobulin M Fc receptor; iCAR: Inhibitory chimeric antigen receptor; ICU: Intensive care unit; IFN-γ: Interferon-γ; Ig: Immunoglobulin; IGH: Immunoglobulin heavy chain; IL: Interleukin; IWCLL: International Workshop on Chronic Lymphocytic Leukemia; MRD: Minimal residual disease; NR: Nonresponding; PD: Progressive disease; PD-1: Programmed cell death protein 1; PET-CT: Positron emission tomography-computed tomography; PR: Partial remission; R/R: Relapsed and refractory; ROR1: Tyrosine kinase-like orphan receptor 1; scFv: Single-chain antibody fragment; SD: Stable disease; STAT3: Signal transducer and activator of transcription 3; $T_{CM}$: Central memory T cells; $T_{EC}$: Effector cells; $T_{EMR}$: Effector memory T cells; $T_{N}$: Naive T cells; TNF: Tumor necrosis factor; $T_{PS}^{S}$: Tumor protein 53, $T_{SCM}^{S}$: T memory stem cells

Acknowledgements
Not applicable

Funding
This study was supported by National Natural Science Foundation of China (8170108002), Jiangsu Province’s Medical Elite Programme (ZDRCA2016022), Project of National Key Clinical Specialty, Jiangsu Provincial Special Program of Medical Science (BL2014086 and BE2017751) and National Science and Technology Major Project (2018ZX09734007).

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions
YZ wrote the initial drafts. WX and JL revised the review and finalized the last version of the article. All authors checked and approved the final version.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China. 2Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China. 3Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.

Received: 21 October 2018 Accepted: 8 November 2018

Published online: 20 November 2018

References
1. Fernandez-Martinez JL, deAndres-Galiana EJ, Sonis ST. Genomic data integration in chronic lymphocytic leukemia. J Gene Med. 2017;19(1–2):e2936.
2. Kim JA, Hwang B, Park SN, Huh S, Im K, Choi S, Chung HY, Huh J, Seo EJ, Lee JH, Bang D, Lee DS. Genomic profile of chronic lymphocytic leukemia in Korea identified by targeted sequencing. PLoS One. 2016;11(12):e0167641.
3. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Ward E, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.

4. Yu S, Li Q, Liu Q, Li T, Yuan X, Han X, Wu K. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.

5. Cheng E, Xu X. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol. 2017;10(1):17.

6. Lorentzen CL, Stenman PT, CD19-chimeric antigen receptor T cells for treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia. Scand J Immunol. 2015;82(4):307–19.

7. Alimabadi H, Walseng E, Kristian A, Myhr MR, Soso EM, Munthe LA, Andersen JT, Wang MY, Kvaale G, Gudmundsson K, Ytge JA. Inclusion of an IgG1-fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 2015;22(5):391–403.

8. Hudecek M, Sommermeyer D, Kosaih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125–35.

9. Jonnalagadda M, Mardros A, Usatik R, Wang X, Hoffman LJ, Bernardie M, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2015;21(12):4091–9.

10. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for Cancer therapy. J Natl Cancer Inst. 2016;108(7). https://doi.org/10.1093/jnci/djv497.

11. Sun J, Sadelain M. The quest for spatio-temporal control of CAR T cells. Sci Transl Med. 2018;10(436):1–13.
40. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(5):59aa7.

41. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8): 725–33.

42. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barret AJO, Ito S, Shpall EJ, Krances RA, Kambale RT, Camran G, Hosing CM, Gee AP, Mei Z, Grilly BJ, Hlesop HE, Rooney CM, Brenner MK, Bolland CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2945–73.

43. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickey DD, Gea-Banacloche JC, Pavletic SZ, Spokes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuber B, Jena B, Bishop JP, Gress RE, Rosenberg SA. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem-cell transplantation. Blood. 2013;122(5):329–39.

44. Brudno JN, Somerville RP, Shi V, Rose JH, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickey DD, Lu TI, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuber B, Hakim FT, Rosenberg SA. Receptor affinity and extracellular domain modifications of CD19-targeted T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2013;31(10):1121–21.

45. Poirot L, Philip B, Schiffer-Manioui C, le Clerc D, Chion-Sotinel I, Derniame S, Potrel P, Bas C, Lemaire L, Galetto R, Lebuhotel C, Eyquem J, Cheung GW, Duclett A, Gouble A, Arnold S, Pegg K, Pule M, Scharenberg AM, Smith J. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 2015;75(18):3853–64.

46. Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Sommermeyer D, Jensen MC, IWamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuber B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2013;31(10):1121–21.

47. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cheriyan S, Hudecek M, Sommermeyer D, Melville K, Budiarto TM, Robinson E, Sommermeyer D, Jensen MC, IWamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuber B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2013;31(10):1121–21.

48. Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobin A, Zinzani PL, Zucca E, Abramson J, Vose J. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017;14(6):335–46.

49. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cheriyan S, Hudecek M, Sommermeyer D, Melville K, Pender B, Riddell SR. Receptor affinity and extracellular domain modifications of CD19-targeted T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2013;31(10):1121–21.

50. Giordano Attianese GM, Marin V, Hoyos V, Savoldo B, Pizzotta I, Tettamanti S, Agostoni V, Parma M, Ponzone M, Bertolaccio MT, Ghia P, Biondi A, Dotti G, Biagi E. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia: new data presented at ASCO 2017. BMC Med. 2017;15(1):156.

51. Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz RJ, Kosasih PL, Rader C, Riddell SR. Safety of targeting ROR1 in CLL following initial purine analog-based therapy. Mol Ther. 2017;25(6):1307–16.

52. Biagi E. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia: new data presented at ASCO 2017. BMC Med. 2017;15(1):156.

53. Yang J, Baskar S, Kwong KY, Kennedy MG, Wienster A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One. 2011;6(6):21018.
70. Fraietta JA, Lacey SF, Orlando EI, Pruteanu-Malinici I, Gohil M, Lundh S, Boeusteanu AC, Wang Y, O’Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MW, Levine BL, Frey NW, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brodgon JL, Porter DL, June CH, Melenhorst JJ. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71.

71. Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel). 2016;8(3). https://doi.org/10.3390/cancers8030036.

72. Hoffmann JM, Schubert ML, Wang L, Huckelhoven A, Seilner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Muller-Tidow C, Dreger P, Schmitt M. Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients. Front Immunol. 2017;8:1956.

73. Riches JC, Davies JK, McClanahan F, Fatiah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(18):3612–21.

74. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hultt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–22.

75. Yin Q, Sinina M, Robinson H, Yusko E, Vignali M, O’Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol. 2017;198(4):1740–7.

76. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492–500.

77. Fraietta JA, Noble CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SI, Bushman FD, June CH, Melenhorst JJ. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307–12.

78. Burger JA, O’Brien S. Evolution of CLL treatment—from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510–27.

79. Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in 8 cell malignancies. J Hematol Oncol. 2017;10(1):35.

80. Zhang LN, Song Y, Liu D. CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. J Hematol Oncol. 2018;11(1):41.

81. Kazakowski D, Xu L, Li Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11(1):91.